跳至主要内容
临床试验/EUCTR2005-005347-25-DE
EUCTR2005-005347-25-DE进行中(未招募)不适用

Impact of 12 weeks of oral niacin on endothelial function, lipid composition and cardiovascular biomarkers in patients with coronary artery disease: A prospective, randomized, double-blind, placebo-controlled, monocentric clinical trial of phase IV - INEF

Johannes Gutenberg-Universität Mainz, II. Med. Klinik (ausführende Stelle), Prof. Dr. med. T. Münzel0 个研究点目标入组 130 人开始时间: 2006年1月23日最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
进行中(未招募)
发起方
入组人数
130

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • -Men or women > 35 and < 80 years of age
  • -Documented clinically stable CAD and known dyslipidemia, defined by a LDL-Cholesterol >70 mg/dl and a HDL-Cholesterol <65mg/dl.
  • -A flow-mediated vasodilatation (FMD) of less than 8%
  • -Ability of subject to understand character and individual consequences of clinical trial
  • -Written informed consent must be available before enrollment in the trial
  • -For women with childbearing potential, adequate contraception.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range

排除标准

  • -Clinical signs of congestive heart failure or left ventricular ejection fraction <30%
  • -Uncontrolled hypertension (blood pressure >180/110mmHg) or hypotension (systolic blood pressure <90 mmHg)
  • -Initiation of any of the following medications within the last twelve weeks: Aspirin, lipid-lowering agents; calcium antagonists;betablockers, ACE-inhibitors or AT1 receptor blockers; hormone replacement therapy
  • -Use of steroids or chemotherapy drugs within the past year or chronic use of nonsteroidal anti-inflammatory drugs except of aspirin
  • -Hemodynamically significant valvular heart disease or hypertrophic obstructive cardiomyopathy
  • -Renal dysfunction (creatinine > 2.5 mg/dl)
  • -Known hepatic disease or elevation of serum transaminases or gGT > 2x ULN (upper limit of normal range)
  • -Uric acid >10,0 mg/dl
  • -Alcohol abuse
  • -WBC >12.000 or platelet count >500.000/µl or <75.000/µl
  • -Existence of acute gastric ulcers
  • -Existence of acute arterial bleeding
  • -Other significant laboratory abnormalities that the investigator feels may compromise the patient’s safety by participation in the study
  • -History of systemic inflammatory disease (rheumatoid arthritis, osteoarthritis, inflammatory bowel disease, systemic lupus erythematous), myositis/myopathic process, or cancer
  • -Known HIV
  • -Malabsorption
  • -Overt hyperthyreodism
  • -Pregnancy and lactation
  • -History of hypersensitivity to the investigational medicinal product or to any drug with similar chemical structure or to any excipient present in the pharmaceutical form of the investigational medicinal product
  • -Participation in other clinical trials and observation period of competing trials, respectively

研究者

发起方
Johannes Gutenberg-Universität Mainz, II. Med. Klinik (ausführende Stelle), Prof. Dr. med. T. Münzel

相似试验